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Abstract
Background: A high burden of tuberculosis (TB) occurs in sub-Saharan African countries and many cases of active TB and
drug-resistant TB remain undiagnosed. Tertiary care hospitals provide an opportunity to study TB co-morbidity with non-
communicable and other communicable diseases (NCDs/CDs). We evaluated the burden of undiagnosed pulmonary TB and
multi-drug resistant TB in adult inpatients, regardless of their primary admission diagnosis, in a tertiary referral centre.
Methodology/Principal Findings: In this prospective study, newly admitted adult inpatients able to produce sputum at the
University Teaching Hospital, Lusaka, Zambia, were screened for pulmonary TB using fluorescent smear microscopy and
automated liquid culture. The burden of pulmonary TB, unsuspected TB, TB co-morbidity with NCDs and CDs was
determined. Sputum was analysed from 900 inpatients (70.6% HIV infected) 277 (30.8%) non-TB suspects, 286 (31.8%) TB
suspects and 337 (37.4%) were already receiving TB treatment. 202/900 (22.4%) of patients had culture confirmed TB. TB co-
morbidity was detected in 20/275 (7.3%) NCD patients, significantly associated with diabetes (P = 0.006, OR 6.571, 95%CI:
1.706–25.3). 27/202 (13.4%) TB cases were unsuspected. There were 18 confirmed cases of MDR-TB, 5 of which were
unsuspected.
Conclusions/Significance: A large burden of unsuspected pulmonary TB co-morbidity exists in inpatients with NCDs and
other CDs. Pro-active sputum screening of all inpatients in tertiary referral centres in high TB endemic countries is
recommended. The scale of the problem of undiagnosed MDR-TB in inpatients requires further study.
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Introduction
The WHO estimates that In 2010, there were 1.45 million TB-
related deaths, with the highest burden of tuberculosis (TB) in sub-
Saharan Africa (SSA), where many cases of active TB and drug-
resistant TB remain undiagnosed [1]. These TB-related deaths
often occur at tertiary referral centres, which concentrate a broad
range of critically ill patients where the primary admission
diagnosis is the focus of medical attention. TB screening
programmes in SSA have traditionally been more community
based and focussed on primary and secondary care facilities [2].
TB cases that are missed at tertiary referral centres in SSA, may be
to some degree symptomatic, but overlooked with the focus of
attention on the main admission symptoms and referral diagnoses.
Missed cases might also result from subclinical/asymptomatic/
incipient TB, although the definitions for these terms are not yet
clear [3,4].
Subclinical TB has been defined as ‘asymptomatic disease in
immunocompromised hosts largely associated with loss of
containment’ [3] and this term has commonly been used in
studies of asymptomatic TB HIV positive cohorts [4,5,6,7,8,9,10]
where active disease is detected through sputum culture [11].
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‘Incipient TB’ has been defined as ‘contained disease in
asymptomatic, relatively immunocompetent persons’ [3] although
broader cohorts which include HIV negative patients, and those
with NCDs, have been less well studied. SSA is facing a growing
NCD burden with diseases such as cardiovascular disease, diabetes
mellitus, chronic respiratory disease and cancers contributing up
to 25% of deaths [12,13,14,15]. There is a growing awareness of
the influence of TB co-morbidity with some NCDs (such as
smoking related lung disease, renal disorders, diabetes, malnutri-
tion, alcohol and drug abuse) [16,17] and understanding this is
increasingly becoming important for TB control [1,18]. MDR-TB
continues to pose a major threat globally, and due to poor
surveillance and testing facilities in developing countries [19], less
than 2% of new TB cases and 6% of retreatment cases being tested
for resistance [1]. Referral centres may concentrate cases of MDR-
TB and if these drug resistant patients are not promptly diagnosed,
isolated and appropriately treated, they pose a major transmission
risk to other patients, hospital staff and visitors.
Zambia has a high TB incidence (462/100,000 population) [1]
but no routine data are collected for MDR-TB and no confirmed
cases were reported to the WHO in 2010 [1,20]. National
guidelines recommend pulmonary TB screening (using sputum
smear microscopy, and automated liquid culture at referral
centres) only in TB suspects: patients who present with ‘a
persistent cough for more than 2 weeks’ [21]. These guidelines
are broadly applied at both primary and tertiary centres. Patients
with subclinical/asymptomatic/incipient TB or those with inter-
mittent symptoms, and those with a more acute co-morbidity, are
possibly missed by this programme. The University Teaching
Hospital (UTH) in Lusaka is Zambia’s main referral centre, with
its internal medicine department receiving an estimated 6000
adult admissions per year (mortality at 183/1000 admissions).
Tertiary care hospitals like UTH provide an opportunity to study
asymptomatic TB, and TB co-morbidity with NCDs and other
CDs. We evaluated the burden of pulmonary TB and multi-drug
resistant TB in adult inpatients, regardless of their primary
admission diagnosis, in a tertiary referral centre in Zambia.
Methods and Study Population
Ethics Approval
This study was approved by the research ethics review
committee of the University of Zambia School of Medicine,
Lusaka, Zambia. All study participants gave written informed
consent and the study was conducted in accordance with ethics
committee guidelines.
Study Design and Setting
A prospective study to assess the burden of pulmonary TB,
MDR-TB, unsuspected TB and co-morbidity with NCDs and
CDs other than TB, irrespective of admission diagnosis and HIV
status, in adult inpatients presenting to UTH, Lusaka, Zambia - a
tertiary referral centre.
Definitions
PTB. Pulmonary tuberculosis.
MDR-TB. TB caused by Mycobacterium tuberculosis (M.tb) strains
resistant to at least isoniazid and rifampicin.
TB suspect. Patient with presence of cough on admission, of
at least 2 weeks’ duration (Zambia National guidelines) [21].
Non-TB suspect. Any patient who is not a TB suspect in
accordance with the above definition.
Current TB Patient. Patient currently on TB therapy,
initiated prior to admission.
Unsuspected TB. Culture confirmed TB in a non-TB
suspect. As our cohort contains a broad range of patients,
including HIV negative, HIV positive (at different stages of
immunosuppression) and NCD patients, we use the term
‘unsuspected TB’ to define all culture confirmed TB in patients
in whom TB was not suspected. These may include subclinical,
asymptomatic, incipient and intermittent cases, as well as
symptomatic cases missed due to co-morbidities.
Communicable Diseases (CDs). Infectious diseases that
can be transmitted between people.
Non-communicable Disease (NCDs). Diseases that cannot
be transmitted between people.
TB co-morbidity. Presence of culture confirmed TB,
presenting with a different disease.
Patient Population and Recruitment
New adult inpatient admissions to UTH were approached
irrespective of admission diagnosis, including TB suspects, non-TB
suspects and current TB patients, and informed consent was
obtained from those willing to participate. The sole inclusion
criterion was that they could produce at least one sputum
specimen for analysis. Clinical details including the admission
diagnosis which necessitated hospital admission were recorded.
Sputum samples were collected. Due to the very high HIV
prevalence in the population, the hospital has in place a Diagnostic
Counselling and Testing (DCT) scheme. The majority of patients
enrolled in the study were tested for HIV, as part of routine
practise on admission. To assess to what degree our cohort of
sputum producers was representative of the general hospital
population, we compared our cohort with a set of 960 hospital
records accounting for all adult admissions over a 2 month period.
Sample Collection
In accordance with routine hospital protocols, clinical staff
supervised the collection of spot sputum from patients, and then
left containers to collect up to two other specimens over the next
24 hours. Sputum induction is not routine at the hospital and was
not performed.
Microscopy, Sputum Culture and Phenotypic Drug
Susceptibility Testing (DST)
Fluorescent smear microscopy was performed directly on
sputum specimens as described previously [22]. For culture,
sputum specimens (2–10 ml) were homogenised and digested in
NALC-NaOH (1.5% final concentration), and vortexed for 30
seconds at 5 minutes intervals for 15 minutes. Samples were then
concentrated at 40006g for 15 minutes, the supernatant was
removed and sediment re-suspended in 5 mls phosphate buffer
(pH 6.8), irrespective of the original sample volume. The resulting
suspension was used to perform Mycobacterial Growth Indicator
Tube (MGIT - BD, Franklin Lakes, NJ, USA) culture. One MGIT
tube was inoculated with 0.5 ml concentrated sputum and
incubated in the BACTEC 960 system (BD, Franklin Lakes, NJ,
USA). For patients who submitted 2 or 3 sputum specimens, the
most mucoid was used for culture. Cultures were considered
negative if no growth was observed after 42 days. Positive MGIT
cultures were confirmed as containing M.tb complex with no
growth on blood agar plates and a positive TBcID (BD) culture
confirmation test. Contaminated samples were retreated and re-
cultured and excluded if still contaminated. Phenotypic DST was
performed on M.tb positive cultures using the BACTEC MGIT
960 SIRE kit (BD, Franklin Lakes, NJ, USA) according to the
manufacturer’s instructions.
Burden of Pulmonary TB in Hospital Inpatients
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Data Management and Analysis
Clinical and laboratory data were compiled in databases using
double data entry and Epidata software [23]. Selected variables
were exported to SPSS v 18 (IBM, Armonk, NY, USA) for
analysis. Univariate comparisons of the proportions of different
patient groups with the hospital population were compared by chi-
squared test. Univariate and multivariate analysis for factors
effecting TB burden in different patient groups was performed
using binary logistic regression.
Results
Study Cohort
During the 15 month period from Sept 2010 to Dec 2011,
we conducted 218 days of recruitment with a median of 4
recruits per day. A total of 964 patients were enrolled, from
whom smear and culture results were obtained for 900 patients
and analysed (Figure 1). A total of 31.8% (286/900) were TB
suspects based on the Zambian National TB Guidelines [21]),
37.4% (337/900) were current TB patients on treatment, and
30.8% (277/900) were non-TB suspects. Comparison with the
overall hospital population (data for all admissions collected
from hospital records over a 2 month period) showed that the
proportion of current TB patients and TB suspects in our study
cohort was significantly greater (1.7 and 3.6 fold respectively =
P,0.0001) than the general inpatient population and that
patients not suspected of having TB were significantly under-
represented (0.4 fold, P,0.0001) (Table 1) as expected (due the
recruitment requirement of sputum production). This illustrates
that sputum can be successfully collected and analysed for TB,
from inpatients admitted with a variety of conditions, not only
those suspected of TB (or other pulmonary conditions).
Unsuspected TB and TB Co-morbidity with HIV
22.4% (202/900) of patients recruited had culture confirmed
TB (Table 2). Univariate regression analysis showed that TB
burden did not differ by gender, but was significantly more likely
in HIV infected patients (P,0.001, OR 2.171 (95%CI: 1.461–
3.022)). HIV prevalence within the cohort was 70.6%, and 82%
(161/197) of all culture confirmed TB cases detected were in HIV
positive patients. With respect to age, there was an annual 2.6%
decrease in the likelihood of TB (P,0.001, OR 0.974 (95% CI:
0.961-0.988)). The burden of culture confirmed TB in both
current TB patients and TB suspects was similar (29.4% (99/337)
and 26.6% (76/286) respectively). Interestingly, 9.7% (27/277) of
non-TB suspects also had culture confirmed active TB (Figure 2),
accounting for 13.4% of all culture confirmed TB cases. Of these
patients, five had a history of TB treatment. Furthermore, five of
eight renal and two of four diabetic culture confirmed TB patients
were from this unsuspected group.
Admission Diagnosis and TB Co-morbidity with other
Communicable and Non-communicable Diseases
275 patients showed clear evidence of admission diagnosis of co-
morbidity with a non-communicable disease. Likewise, 306
patients presented with communicable diseases (excluding TB
and HIV) (Table 2). Admission diagnoses of PTB or EPTB and
those that could not be categorically assigned to either group (eg.
anaemia) were excluded from this analysis. 20/275 (7.3%) patients
with NCDs, and 74/306 (24.2%) patients with CDs were found to
have active TB. Binary logistic regression analysis, controlling for
the effects of HIV and age, shows that among the NCD patient
group, the burden of TB was significantly greater in diabetes
patients (P = 0.025, OR 6.571 [95%CI: 1.706–25.302]) patients,
although due to the small numbers in these patient categories, the
confidence intervals are broad. Within the CD patients, TB co-
Figure 1. Patient Recruitment Summary.
doi:10.1371/journal.pone.0040774.g001
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morbidities were as prevalent among gastrointestinal and CNS
patients, as among respiratory patients, showing that TB co-
morbidity should be considered in patients with respiratory and
non-respiratory infections (Table 2).
Culture Confirmed MDR-TB
Culture DST results were available for 111 cases, of which 18
(16.2%) were MDR-TB. 33 sub-cultures were contaminated and
58 were not performed as DST was not available at the beginning
of the study. All 18 MDR-TB cases detected were in current or
suspected TB patients. Of the 18 MDR-TB cases, 12 were on or
about to start relapse treatment. The remaining 6 MDR-TB cases
were on their first course of treatment and 5 of these were not
suspected by the attending physician.
Discussion
This study found a large burden of pulmonary TB in sputum
producing inpatients at a high HIV burden tertiary referral centre
in Zambia. The high TB case load (22.4%: 202/900) among
patients able to expectorate was anticipated in a patient cohort
with an HIV prevalence of 70.6%, where over 80% of all culture
confirmed TB cases were associated with HIV. Despite moderate
reductions in both HIV and TB prevalence in Zambia [2,20],
tertiary referral centres like UTH will continue to admit large
numbers of HIV and TB/HIV co-infected patients for the
foreseeable future. In this study there were three other key
findings: a) 27 out of 202 (13.4%) TB cases were unsuspected on
admission and would have remained undiagnosed if not actively
screened on this study; b) A total of 94 TB cases presented as co-
morbidity with other diseases, 20 of which were NCDs; c) 18 out of
111 (16.2%) TB cases tested were MDR-TB and 5 out of these 18
(27.8%) MDR-TB cases were not suspected in the differential
diagnosis on admission. These findings highlight that many TB
and MDR-TB cases remain undiagnosed, and that passive case
finding using current clinical criteria outlined in the Zambia
National TB Program national guidelines for investigating
suspected TB cases, are inadequate for use in inpatients at
UTH. Furthermore, these findings raise concerns over TB and
MDR-TB transmission within the hospital and highlight the need
for more focussed investments into active screening and surveil-
lance for both TB and MDR-TB.
This study was uniquely designed to focus not only on screening
of inpatients who were suspected of having active pulmonary TB
on admission by the admitting physician, but also to determine the
extent to which TB cases were being missed, and the burden of TB
co-morbidity with NCDs and CDs. We recruited roughly equal
numbers of TB suspects, non-TB suspects and current TB patients
on treatment. The relative proportions of these three groups to be
recruited were not pre-determined, with study clinical officers
instructed to approach all admissions. That roughly one third of
the cohort were not suspected of TB, yet able to expectorate and
recruited onto the study was surprising, and shows that a broader
range of patients than you might expect, can expectorate and
could be readily screened for TB. Across the cohort as a whole, a
broad range of patients were recruited, with 75.3% (678/900) of
patients having an admission diagnosis other than TB, including
NCDs and CDs.
Several African studies have reported HIV-associated subclin-
ical TB infections in which patients do not present with any
symptoms of active TB [4,8,11]. In this study, the cohort
contained both HIV positive and negative patients, and those
Table 1. Study population demographics.
Hospital Population (n =960)
Study
(n =900) Significancea
Median (IQR) age (Years) 36 (29–48) 35 (28–43)
Sex (Male) 49.4% (471/954) 50.2% (452/898) P = 0.679
HIV infection 63.1% (536/849) 67.3% (606/858) P = 0.001
TB status
Current TB 22.4% (214/957) 37.4% (337/900) P,0.001
TB suspects 8.8% (84/957) 31.8% (286/900) P,0.001
Non-TB suspects 68.7% (659/957) 30.8% (277/900) P,0.001
Admission Diagnosis n = 946b
Respiratory Disorders (excluding TB) 95 (10.0%) 155 (17.2%) P,0.001
PTB 72 (7.6%) 176 (19.6%) P,0.001
EPTB 54 (5.7%) 56 (6.2%) P = 0.641
CNS disorders 156 (16.5%) 92 (10.2%) P = 0.001
Cancer 33 (3.5%) 40 (4.4%) P = 0.292
Cardiac Disorders 166 (17.5%) 125 (13.9%) P = 0.031
Gastrointestinal Disorders 70 (7.4%) 58 (6.4%) P = 0.419
Metabolic Disorders 100 (10.6%) 37 (4.1%) P,0.001
Renal Disorders 38 (4.0%) 47 (5.2%) P = 0.217
Diabetes 57 (6.0%) 19 (2.1%) P,0.001
Other 105 (11.1%) 94 (10.4%) P = 0.650
IQR – interquartile range; TB – tuberculosis; PTB – pulmonary TB; EPTB - extrapulmonary TB; CNS – central nervous system.
aPearson chi-squared test.
bAdmission diagnosis could not be gathered from 14 admissions.
doi:10.1371/journal.pone.0040774.t001
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with a broad range of co-morbidities with other diseases, and so we
use the term ‘unsuspected TB’ to define all culture confirmed TB
cases in patients in whom TB was not suspected at admission.
These unsuspected cases accounted for 13.4% (27/202) of all
culture confirmed TB cases. Some of these cases may have been
identified if more rigorous symptom based case definitions were
available, with improved clinical awareness of the possibility of TB
in all inpatients, coupled with better trained and less over-worked
staff, and improved access to good quality radiography and
laboratory services. Likewise, some of these unsuspected cases may
fall into proposed definitions for subclinical or incipient TB [3].
Whether subclinical, incipient or broadly symptomatic but
overlooked due to co-morbidity with other diseases, a simple
screening policy for all inpatients who can expectorate, using the
locally available screening services, would detect these cases. 37%
(10/27) of unsuspected cases were smear positive by microscopy,
so even in centres where culture services are not available,
significant numbers of cases could be captured with this policy.
We showed, as seen in other SSA countries, that HIV positive
patients are twice as likely to have active pulmonary TB, with two
thirds of TB patients co-infected with HIV [24]. Many TB/HIV
patients also have NCDs or opportunistic CDs. With respect to
unsuspected TB, HIV was no more prevalent in the unsuspected,
than in suspected TB cases, showing that in both HIV positive and
negative patients, classical symptoms of pulmonary TB may be
absent or overlooked [25].
The growing problem of NCDs in SSA is well documented
[12,13,14,15], but there are only few reports that have addressed
TB co-morbidity with NCDs and CDS other than TB [1,18,24].
In this study, roughly half the TB cases were co-morbidities with
other NCDs and CDs. Within the NCD group, there was a
significantly higher likelihood of TB co-morbidity in patients with
renal disorders and those with diabetes compared to other NCD
patients, an association that has been documented elsewhere
[17,18]. These two patient groups also featured prominently in the
unsuspected TB cases, indicating that these NCD presentations
are possibly masking TB. Amongst 306 patients with a CD
admission diagnoses other than TB, culture confirmed TB was
detected in 74 patients (24.2%), and interestingly, TB was no more
commonly detected in patients with other respiratory infections,
verses those with CNS or gastrointestinal infections and the
likelihood of culture confirmed TB was no greater in respiratory
patients in both univariate and multivariate analysis (controlling
for the effects of HIV and age). This demonstrates that TB can
underlie a broad range of infectious diseases and screening
programmes should not just focus on respiratory patients.
Our data show that MDR-TB and unsuspected MDR-TB are
significant problems in inpatients at UTH. In our study, of those
culture positive cases analysed by culture DST, 18 out of 111
(16.2%) had MDR-TB and 5 were undiagnosed, on inappropriate
therapy with first line TB treatment, and were not suspected of
MDR-TB by the attending physician. This represents a significant
failure to adequately diagnose and treat MDR-TB, putting other
patients and staff at unnecessary risk. A more pro-active routine
screening program for TB and MDR-TB is required. This finding
is confluent with the fact that MDR-TB surveillance in Zambia is
poor, with MDR-TB data not being routinely collected in
hospitals or primary health care facilities, due to under-funding
and inadequate laboratory services [1,2,20].
As this was a prospective descriptive study to evaluate the
burden of TB in sputum producing new inpatient admissions using
diagnostics that require disease-associated specimens, our patient
cohort is not representative of the broader hospital population.
Through comparison with hospital admissions data, we confirmed
that patients with respiratory illnesses and TB patients were over
represented and so we make no claim about the prevalence of TB
within the general inpatient population. There were also factors
which could have contributed to missing some TB cases.
Performing culture on multiple specimens, using sputum induction
and extensive investigations for extrapulmonary TB would have
Figure 2. TB prevalence in different patient groups stratified by HIV status (HIV status was available for 858/900 study
participants).
doi:10.1371/journal.pone.0040774.g002
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likely yielded more cases. Despite these limitations, the high TB
burden (diagnosed and undiagnosed); co-morbidity with NCDs;
and the identification of MDR-TB in inpatients able to produce
sputum, calls for more pro-active screening for TB in medical
inpatients using routine diagnostic protocols already in place.
Most countries in SSA are now moving away from vertical
programmes for TB and HIV services and more emphasis is on
merging TB/HIV services for delivery of joint care [2,26]. The
significant number of unsuspected TB cases seen here, missed in
part due to co-morbidity with NCDs, calls for more pro-active
screening of all inpatient admissions locally, and should be
considered by other hospitals in the region. The majority of
unsuspected cases detected did not have a history of TB. These un-
detected active TB cases are being admitted to a tertiary referral
centre, where 70% of inpatients are HIV positive, presenting a
high transmission risk. With increasing awareness of the co-
morbidity between NCDs and TB, it would be appropriate to
incorporate a unified health service to deal with all diseases
affecting the population. Within this programme, pro-active
screening for TB in those seeking care, capable of producing
sputum, is appropriate in light of our findings.
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